Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

B0125

Sigma-Aldrich

Bacitracin

from Bacillus licheniformis, ≥65 IU/mg

Sinonimo/i:

Altracin, Bacitracin A

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C66H103N17O16S
Numero CAS:
Peso molecolare:
1422.69
Numero CE:
Numero MDL:
Codice UNSPSC:
51282002
ID PubChem:
NACRES:
NA.76

Origine biologica

Bacillus licheniformis

Livello qualitativo

Forma fisica

powder

Attività specifica

≥65 IU/mg

Spettro attività antibiotica

Gram-positive bacteria

Modalità d’azione

cell wall synthesis | interferes

Temperatura di conservazione

2-8°C

Stringa SMILE

[H]N1[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)C3CSC(=N3)C(N)C(C)CC)[C@@H](C)CC)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](Cc4ccccc4)C1=O

InChI

1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1
CLKOFPXJLQSYAH-RNHDWVCBSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Chemical structure: peptide

Applicazioni

Bacitracin is used to study disruption of bacterial cell wall synthesis at the level of peptidoglycan cross-linking and isoprenyl metabolism.

Azioni biochim/fisiol

Bacitracin is a peptide antibiotic.
Antimicrobial spectrum: Gram-positive bacteria.
Mode of Action: Inhibits bacterial cell wall synthesis by inhibiting dephosphorylation of lipid pyrophosphate.

Altre note

Keep container tightly closed in a dry and well-ventilated place.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Tansol Park et al.
Frontiers in microbiology, 8, 1189-1189 (2017-07-14)
Axenic cultures of free-living aerobic ciliates, such as
Xavier d'Anglemont de Tassigny et al.
Endocrinology, 149(8), 3926-3932 (2008-05-03)
The G protein-coupled receptor GPR54, and its peptide ligand kisspeptin (Kp), are crucial for the induction and maintenance of mammalian reproductive function. GPR54 is expressed by GnRH neurons and is directly activated by Kp to stimulate GnRH release. We hypothesized
Hiromasa Tsuda et al.
Antimicrobial agents and chemotherapy, 46(12), 3756-3764 (2002-11-19)
Streptococcus mutans is resistant to bacitracin, which is a peptide antibiotic produced by certain species of Bacillus. The purpose of this study was to clarify the bacitracin resistance mechanism of S. mutans. We cloned and sequenced two S. mutans loci
Kazuhiko Nakano et al.
Nature communications, 2, 485-485 (2011-09-29)
Although several risk factors for stroke have been identified, one-third remain unexplained. Here we show that infection with Streptococcus mutans expressing collagen-binding protein (CBP) is a potential risk factor for haemorrhagic stroke. Infection with serotype k S. mutans, but not
Pallavi Mandal et al.
The Lancet. Respiratory medicine, 2(6), 455-463 (2014-04-11)
Bronchiectasis is characterised by chronic cough, sputum production, and recurrent chest infections. Pathogenesis is poorly understood, but excess neutrophilic airway inflammation is seen. Accumulating evidence suggests that statins have pleiotropic effects; therefore, these drugs could be a potential anti-inflammatory treatment

Articoli

Inhibition of Cell Wall Biosynthesis by Antibiotics

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.